Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive strategy.

U.S. equities advanced at midday as President Donald Trump announced a new trade deal with the United Kingdom. The Dow Jones ...

Those projections include the impact of tariffs as of May 1, but since that situation might change, there's some uncertainty. Despite the factors that led to its post-earnings decline, Eli Lilly ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly and Company has earned a consensus rating of “Moderate Buy” from 21 analyst firms, showing solid investor ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Analysts appear to be crushing hard on Eli Lilly, with 18 out of 21 giving it a “Buy” rating, despite its sky-high valuation.

ProQR Therapeutics N.V.’s PRQR share price has dipped by 5.53%, which has investors questioning if this is right time to buy.

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...